Detalles de la búsqueda
1.
Longitudinal analysis of circulating tumor cell numbers improves tracking metastatic breast cancer progression.
Sci Rep;
14(1): 12924, 2024 06 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-38839863
2.
Breast cancer but not the menopausal status is associated with small changes of the gut microbiota.
Front Oncol;
14: 1279132, 2024.
Artículo
en Inglés
| MEDLINE | ID: mdl-38327745
3.
Expression of Soluble Form of Aurora A as a Predictive Factor for Neoadjuvant Therapy in Breast Cancer Patients: A Single-Center Pilot Study.
Cancers (Basel);
15(22)2023 Nov 16.
Artículo
en Inglés
| MEDLINE | ID: mdl-38001709
4.
Prognostic value of coronary atherosclerosis and CAC score for the risk of chemotherapy-related cardiac dysfunction (CTRCD): The protocol of ANTEC study.
PLoS One;
18(8): e0288146, 2023.
Artículo
en Inglés
| MEDLINE | ID: mdl-37590267
5.
Eligibility criteria in clinical trials in breast cancer: a cohort study.
BMC Med;
21(1): 240, 2023 07 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-37400830
6.
Immediate breast reconstruction in breast cancer patients with the use of Serasynth and SeragynBR synthetic meshes. Single-oncological center experience, analysis of complications.
Pol Przegl Chir;
96(2): 11-20, 2023 Oct 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-38629281
7.
PD-L1-Positive High-Grade Triple-Negative Breast Cancer Patients Respond Better to Standard Neoadjuvant Treatment-A Retrospective Study of PD-L1 Expression in Relation to Different Clinicopathological Parameters.
J Clin Med;
11(19)2022 Sep 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-36233396
8.
The Impact of Dietary Counselling on Achieving or Maintaining Normal Nutritional Status in Patients with Early and Locally Advanced Breast Cancer Undergoing Perioperative Chemotherapy.
Nutrients;
14(12)2022 Jun 18.
Artículo
en Inglés
| MEDLINE | ID: mdl-35745270
9.
Neoadjuvant Pertuzumab Plus Trastuzumab in Combination with Docetaxel and Carboplatin in Patients with HER2-Positive Breast Cancer: Real-World Data from the National Institute of Oncology in Poland.
Cancers (Basel);
14(5)2022 Feb 26.
Artículo
en Inglés
| MEDLINE | ID: mdl-35267525
10.
Intracranial Response Rate in Patients with Breast Cancer Brain Metastases after Systemic Therapy.
Cancers (Basel);
14(4)2022 Feb 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-35205723
11.
Health-related quality of life in older patients with HER2+ metastatic breast cancer: Comparing pertuzumab plus trastuzumab with or without metronomic chemotherapy in a randomised open-label phase II clinical trial.
J Geriatr Oncol;
13(5): 582-593, 2022 06.
Artículo
en Inglés
| MEDLINE | ID: mdl-35101364
12.
Limitations of Systemic Oncological Therapy in Breast Cancer Patients with Chronic Kidney Disease.
J Oncol;
2020: 7267083, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32508921
13.
Effects of BRCA Germline Mutations on Triple-Negative Breast Cancer Prognosis.
J Oncol;
2020: 8545643, 2020.
Artículo
en Inglés
| MEDLINE | ID: mdl-32322271
14.
Buparlisib plus fulvestrant versus placebo plus fulvestrant for postmenopausal, hormone receptor-positive, human epidermal growth factor receptor 2-negative, advanced breast cancer: Overall survival results from BELLE-2.
Eur J Cancer;
103: 147-154, 2018 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-30241001
15.
Determinants of prolonged survival for breast cancer patient groups with leptomeningeal metastasis (LM).
J Neurooncol;
138(1): 191-198, 2018 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-29435818
16.
Improving Fertility Preservation in Breast Cancer Patients.
J Adolesc Young Adult Oncol;
7(2): 258, 2018 04.
Artículo
en Inglés
| MEDLINE | ID: mdl-29315007
17.
Buparlisib plus fulvestrant versus placebo plus fulvestrant in postmenopausal, hormone receptor-positive, HER2-negative, advanced breast cancer (BELLE-2): a randomised, double-blind, placebo-controlled, phase 3 trial.
Lancet Oncol;
18(7): 904-916, 2017 07.
Artículo
en Inglés
| MEDLINE | ID: mdl-28576675
18.
Retracing Circulating Tumour Cells for Biomarker Characterization after Enumeration.
J Circ Biomark;
4: 5, 2015.
Artículo
en Inglés
| MEDLINE | ID: mdl-28936241
19.
Correlation between CA-125 serum level and response by RECIST in a phase III recurrent ovarian cancer study.
Gynecol Oncol;
122(2): 350-5, 2011 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-21546066
20.
Motesanib, or open-label bevacizumab, in combination with paclitaxel, as first-line treatment for HER2-negative locally recurrent or metastatic breast cancer: a phase 2, randomised, double-blind, placebo-controlled study.
Lancet Oncol;
12(4): 369-76, 2011 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-21429799